Regulation of aerobic glycolysis by long non-coding RNAs in cancer

Xiang-Zhen Kong1, Shou-Sen Hu2, Zhi Sun1

  • 1Department of Pharmacy, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan 450052, China.

Insights

Long non-coding RNAs (lncRNAs) are key regulators of aerobic glycolysis in cancer. Understanding lncRNA roles in this process offers new therapeutic strategies for cancer treatment.

Area of Science:

  • Molecular Biology
  • Cancer Research
  • Biochemistry

Background:

  • Long non-coding RNAs (lncRNAs) are increasingly recognized for their roles in cellular processes.
  • Emerging evidence links lncRNAs to the regulation of cancer metabolism.
  • Aerobic glycolysis is a hallmark of cancer, presenting a potential therapeutic target.

Purpose of the Study:

  • To review recent findings on the role of lncRNAs in aerobic glycolysis.
  • To elucidate the mechanisms by which lncRNAs influence cancer metabolism.
  • To explore the therapeutic potential and challenges of targeting lncRNAs in cancer.

Main Methods:

  • Literature review of recent studies on lncRNAs and cancer metabolism.
  • Analysis of proposed molecular mechanisms.
  • Discussion of therapeutic implications.

Main Results:

  • lncRNAs are implicated in regulating various aspects of aerobic glycolysis in cancer.
  • Specific lncRNAs have been identified as modulators of cancer cell metabolism.
  • Understanding these roles opens avenues for novel cancer therapies.

Conclusions:

  • lncRNAs represent a significant class of molecules involved in cancer's metabolic reprogramming.
  • Targeting lncRNAs offers promising, yet challenging, strategies for cancer treatment.
  • Further research is needed to fully harness lncRNAs for therapeutic benefit.

Related Concept Videos

lncRNA - Long Non-coding RNAs02:39

lncRNA - Long Non-coding RNAs

In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
10.1K
lncRNA - Long Non-coding RNAs02:39

lncRNA - Long Non-coding RNAs

3.8K
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
7.3K
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

4.2K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
5.0K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

1.6K